Guner, A. Et Al. 2020. Clinical safety and efficacy of thrombolytic therapy with low-dose prolonged infusion of tissue type plasminogen activator in patients with intermediate-high risk pulmonary embolism. BLOOD COAGULATION & FIBRINOLYSIS , vol.31, no.8 , 536-542.

Guner, A., Kalcik, M., Aykan, A. C., Gursoy, M. O., Kalkan, A. K., Astarcioglu, M. A., ... Erturk, M.(2020). Clinical safety and efficacy of thrombolytic therapy with low-dose prolonged infusion of tissue type plasminogen activator in patients with intermediate-high risk pulmonary embolism. BLOOD COAGULATION & FIBRINOLYSIS , vol.31, no.8, 536-542.

Guner, Ahmet Et Al. "Clinical safety and efficacy of thrombolytic therapy with low-dose prolonged infusion of tissue type plasminogen activator in patients with intermediate-high risk pulmonary embolism," BLOOD COAGULATION & FIBRINOLYSIS , vol.31, no.8, 536-542, 2020

Guner, Ahmet Et Al. "Clinical safety and efficacy of thrombolytic therapy with low-dose prolonged infusion of tissue type plasminogen activator in patients with intermediate-high risk pulmonary embolism." BLOOD COAGULATION & FIBRINOLYSIS , vol.31, no.8, pp.536-542, 2020

Guner, A. Et Al. (2020) . "Clinical safety and efficacy of thrombolytic therapy with low-dose prolonged infusion of tissue type plasminogen activator in patients with intermediate-high risk pulmonary embolism." BLOOD COAGULATION & FIBRINOLYSIS , vol.31, no.8, pp.536-542.

@article{article, author={Ahmet Guner Et Al. }, title={Clinical safety and efficacy of thrombolytic therapy with low-dose prolonged infusion of tissue type plasminogen activator in patients with intermediate-high risk pulmonary embolism}, journal={BLOOD COAGULATION & FIBRINOLYSIS}, year=2020, pages={536-542} }